0.8918
price up icon2.67%   0.0232
after-market Dopo l'orario di chiusura: .89 -0.0018 -0.20%
loading

Invivyd Inc Borsa (IVVD) Ultime notizie

pulisher
Jun 16, 2026

H.C. Wainwright reiterates Invivyd stock rating on trial progress - Investing.com

Jun 16, 2026
pulisher
Jun 16, 2026

Invivyd completes enrollment in Phase 3 COVID antibody trial - Investing.com

Jun 16, 2026
pulisher
Jun 16, 2026

Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine - The Manila Times

Jun 16, 2026
pulisher
Jun 16, 2026

COVID antibody faces mRNA shots in Phase 3 side-effect study - Stock Titan

Jun 16, 2026
pulisher
Jun 16, 2026

Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Rezolute (RZLT) and Invivyd (IVVD) - The Globe and Mail

Jun 16, 2026
pulisher
Jun 15, 2026

IVVD Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus

Jun 15, 2026
pulisher
Jun 12, 2026

IVVD Stock Quote Price and Forecast - CNN

Jun 12, 2026
pulisher
Jun 11, 2026

Invivyd Inc (IVVD) Reports Clinical Progress. Stock Expected to Explode - Insider Monkey

Jun 11, 2026
pulisher
Jun 11, 2026

Billionaire Lee Ainslie’s 10 Stocks with Huge Upside Potential - Insider Monkey

Jun 11, 2026
pulisher
Jun 10, 2026

IVVD,VCEL Revenue Breakdown - Finviz

Jun 10, 2026
pulisher
Jun 09, 2026

IVVD Reiterated by BTIG -- Price Target Maintained at $10 - GuruFocus

Jun 09, 2026
pulisher
Jun 09, 2026

Invivyd doses first participants in Phase 3 COVID-19 trial - Yahoo! Finance Canada

Jun 09, 2026
pulisher
Jun 09, 2026

Invivyd doses first participants in Phase 3 LIBERTY trial - grafa.com

Jun 09, 2026
pulisher
Jun 09, 2026

Small cap wrap: Royal Road Minerals, Miivo Holdings, Alvopetro, Arizona Gold & Silver... - Proactive financial news

Jun 09, 2026
pulisher
Jun 09, 2026

Invivyd doses first participants in COVID-19 vaccine trial By Investing.com - Investing.com Australia

Jun 09, 2026
pulisher
Jun 09, 2026

Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-A - The Manila Times

Jun 09, 2026
pulisher
Jun 09, 2026

Invivyd doses first participants in COVID-19 vaccine trial - Investing.com

Jun 09, 2026
pulisher
Jun 09, 2026

New COVID shot alternative faces off with mRNA vaccine in Invivyd trial - Stock Titan

Jun 09, 2026
pulisher
Jun 09, 2026

InvivydExpects Liberty Trial Topline Data In Q3 2026 - TradingView

Jun 09, 2026
pulisher
Jun 08, 2026

We Think Invivyd (NASDAQ:IVVD) Can Afford To Drive Business Growth - Moomoo

Jun 08, 2026
pulisher
Jun 07, 2026

InVivo Therapeutics Holdings Corp (NVIV) - Minichart

Jun 07, 2026
pulisher
Jun 06, 2026

This Invivyd Insider Increased Their Holding In The Last Year - Yahoo Finance

Jun 06, 2026
pulisher
Jun 05, 2026

INVIVYD INC (IVVD) Stock Chart - ChartMill

Jun 05, 2026
pulisher
Jun 04, 2026

IVVD News | INVIVYD INC (NASDAQ:IVVD) - ChartMill

Jun 04, 2026
pulisher
Jun 03, 2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Jun 03, 2026
pulisher
Jun 03, 2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 03, 2026
pulisher
Jun 03, 2026

Invivyd offers stock options to 17 new hires at $1.22 each - Stock Titan

Jun 03, 2026
pulisher
Jun 02, 2026

Invivyd Shareholder Notice - TMX Newsfile

Jun 02, 2026
pulisher
Jun 02, 2026

Invivyd Inc stock (US46186M1080): focus on upcoming Jefferies conference and COVID-19 prevention tri - AD HOC NEWS

Jun 02, 2026
pulisher
Jun 02, 2026

Invivyd Shareholder Action Reminder - TMX Newsfile

Jun 02, 2026
pulisher
Jun 01, 2026

IVVD Reiterated by BTIG -- Price Target Maintained at $10.00 - GuruFocus

Jun 01, 2026
pulisher
Jun 01, 2026

Invivyd completes enrollment in COVID-19 prevention trial - Investing.com UK

Jun 01, 2026
pulisher
Jun 01, 2026

Invivyd completes enrollment in COVID-19 prevention trial By Investing.com - Investing.com Australia

Jun 01, 2026
pulisher
Jun 01, 2026

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID - The Manila Times

Jun 01, 2026
pulisher
Jun 01, 2026

Invivyd Announces Completion of Enrollment in Phase 3 DECLARATION Trial for VYD2311 in COVID-19 Prevention - Quiver Quantitative

Jun 01, 2026
pulisher
Jun 01, 2026

COVID antibody trial fully enrolled as Invivyd targets Q3 2026 results - Stock Titan

Jun 01, 2026
pulisher
May 30, 2026

Invivyd Q1 2026 earnings preview - MSN

May 30, 2026
pulisher
May 28, 2026

Invivyd Q1 earnings call highlights - MSN

May 28, 2026
pulisher
May 27, 2026

Invivyd to present at multiple investor events in June, highlighting its latest biopharma developments. - Pluang

May 27, 2026
pulisher
May 27, 2026

Invivyd to Participate in Upcoming Investor Events - The Manila Times

May 27, 2026
pulisher
May 26, 2026

BTIG Maintains Invivyd(IVVD.US) With Buy Rating, Maintains Target Price $10 - Moomoo

May 26, 2026
pulisher
May 21, 2026

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026 - 富途牛牛

May 21, 2026
pulisher
May 21, 2026

Invivyd (IVVD) director Ajay Royan receives stock options for 50,000 shares - Stock Titan

May 21, 2026
pulisher
May 21, 2026

Invivyd (IVVD) director receives grant of 50,000 stock options at $1.04 - Stock Titan

May 21, 2026
pulisher
May 21, 2026

Invivyd (IVVD) director Terrance McGuire granted 50,000 stock options at $1.04 - Stock Titan

May 21, 2026
pulisher
May 21, 2026

Invivyd (IVVD) director receives 50,000 options at $1.04 strike price - Stock Titan

May 21, 2026
pulisher
May 21, 2026

Invivyd grants options to director Paul Bolno | IVVD Insider Trading - Stock Titan

May 21, 2026
pulisher
May 21, 2026

Invivyd (IVVD) director Tamsin Berry receives stock options for 50,000 shares - Stock Titan

May 21, 2026
$30.41
price up icon 1.27%
$55.40
price up icon 6.27%
$89.50
price down icon 1.43%
$54.21
price down icon 0.11%
ONC ONC
$263.92
price down icon 1.60%
$156.58
price down icon 2.17%
Capitalizzazione:     |  Volume (24 ore):